ATE299023T1 - Integrinrezeptor antagonisten - Google Patents

Integrinrezeptor antagonisten

Info

Publication number
ATE299023T1
ATE299023T1 AT98963893T AT98963893T ATE299023T1 AT E299023 T1 ATE299023 T1 AT E299023T1 AT 98963893 T AT98963893 T AT 98963893T AT 98963893 T AT98963893 T AT 98963893T AT E299023 T1 ATE299023 T1 AT E299023T1
Authority
AT
Austria
Prior art keywords
beta
alpha
receptor antagonists
integrin receptor
compounds
Prior art date
Application number
AT98963893T
Other languages
German (de)
English (en)
Inventor
Mark E Duggan
James J Perkins
Robert S Meissner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807384.4A external-priority patent/GB9807384D0/en
Priority claimed from GBGB9815803.3A external-priority patent/GB9815803D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE299023T1 publication Critical patent/ATE299023T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98963893T 1997-12-17 1998-12-14 Integrinrezeptor antagonisten ATE299023T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6990997P 1997-12-17 1997-12-17
GBGB9807384.4A GB9807384D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
US8325098P 1998-04-27 1998-04-27
US9263098P 1998-07-13 1998-07-13
GBGB9815803.3A GB9815803D0 (en) 1998-07-21 1998-07-21 Vitronectin receptor antagonists
PCT/US1998/026485 WO1999030713A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE299023T1 true ATE299023T1 (de) 2005-07-15

Family

ID=27517454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963893T ATE299023T1 (de) 1997-12-17 1998-12-14 Integrinrezeptor antagonisten

Country Status (8)

Country Link
EP (1) EP1044001B1 (enExample)
JP (1) JP2002508326A (enExample)
AT (1) ATE299023T1 (enExample)
AU (1) AU738452B2 (enExample)
CA (1) CA2315232A1 (enExample)
DE (1) DE69830806T2 (enExample)
ES (1) ES2243015T3 (enExample)
WO (1) WO1999030713A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100506A4 (en) * 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
JP2002522540A (ja) * 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
CA2368049A1 (en) 1999-04-13 2000-10-19 Basf Aktiengesellschaft Integrin receptor ligands
AU749351B2 (en) 1999-06-02 2002-06-27 Merck & Co., Inc. Alpha V integrin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
JP2003510360A (ja) 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
AU780364B2 (en) 2000-01-20 2005-03-17 Merck Sharp & Dohme Corp. Alpha V integrin receptor antagonists
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
AU9259801A (en) 2000-09-14 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
US6855722B2 (en) 2001-01-29 2005-02-15 Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
US7115596B2 (en) 2002-12-20 2006-10-03 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
FI3929196T3 (fi) 2013-09-24 2023-10-02 Fujifilm Corp Typpeä sisältävän yhdisteen tai sen suolan tai niiden metallikompleksin farmaseuttinen koostumus
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
SG11202101913PA (en) 2018-08-29 2021-03-30 Morphic Therapeutic Inc INHIBITING aV ß6 INTEGRIN
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EP1044001A1 (en) 2000-10-18
ES2243015T3 (es) 2005-11-16
AU738452B2 (en) 2001-09-20
EP1044001A4 (en) 2003-01-29
DE69830806D1 (de) 2005-08-11
AU1912899A (en) 1999-07-05
CA2315232A1 (en) 1999-06-24
DE69830806T2 (de) 2006-04-27
JP2002508326A (ja) 2002-03-19
WO1999030713A1 (en) 1999-06-24
EP1044001B1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
ATE294163T1 (de) Integrin-rezeptor-antagonisten
ATE298338T1 (de) Integrin-rezeptor-antagonisten
ATE299023T1 (de) Integrinrezeptor antagonisten
ATE236626T1 (de) Integrin antagonist
CA2277273A1 (en) Integrin antagonists
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
ATE368462T1 (de) Alpha v integrin-rezeptor antagonisten
YU38200A (sh) Antagonisti integrinskog receptora
YU38300A (sh) Antagonisti integrinskog receptora
ECSP992897A (es) Antagonistas del receptor de integrina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties